![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Altaras MM., Aviram R., Cohen I., Cordoba M., Yarkoni S. and Beyth Y. (1993) Role of prolonged stimulation of tamoxifen therapy in etiology of endometrial sarcomas. Gynecologic Oncology, 49, 255–258.
- Boccardo F., Bruzzi P., Rugagotti A., Nicolo G. and Rosso R. (1981) Estrogen like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology, 38, 281–285.
- Clarke M.R. (1993) Uterine malignant mixed mullerian tumour in a patient on long-term tamoxifen therapy for breast cancer. Gynecologic Oncology, 51, 411–415.
- Evans M.J., Langlois N.E.I., Kitchener H.C. and Miller I.D. (1995) Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malig-nant mixed Mullerian tumor) of the uterus? International Journal of Gynaecologic Cancer, 5, 310–313.
- Fornander T., Rutquist L., Cedermark B., Glas U., Mattsson A., Silversward C., Skoog L., Somell A., Theve T. and Wilking N. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 2, 117–120.
- Fotiou S., Hatjieleftheriou G., Kyrousis G., Kokka F. and Apostolikas N. (2000) Long term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: 2 case reports and review of the literature. Anticancer Research, 20, 2015–2020.
- Gottlieb S. (2002) Tamoxifen may increase the risk of uterine sarcoma. British Medical Journal, 325, 7.
- Hardell L. (1988) Tamoxifen as risk factor for carcinoma of the corpus uteri. Lancet, 2, 563.
- Harlow B.L., Weiss N.S. and Lofton S. (1986) The epide-miology of sarcomas of the uterus. Journal of the National Cancer Institute, 76, 399–402.
- Ismail S.M. (1994) Pathology of endometrium treated with tamoxifen. Journal of Clinical Pathology, 47, 827–833.
- Klopper A. and Hall M. (1971) New synthetic agent for the induction of ovulation: preliminary trial in women. British Medical Journal, 2, 152–154.
- Love R., Bosch F., Hamilton C., Gill P., Hossfeld D., Sherman C., Kirk C. and Sahel H. (1994) Manual of Clinical Oncology, 6th edn, p. 350. Berlin, Springer-Verlag.
- Magriples U., Naftolin F., Schwartz P.E. and Carcangiu M.L. (1993) High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. Journal of Clinical Oncology, 11, 485–490.
- McCluggage W.G., McManus D.T., Lioe T.F. and Hill C.M. (1997) Uterine carcinosarcoma in association with tamoxifen therapy. British Journal of Obstetrics and Gynaecology, 104, 748–750.
- Rachmaninoff N. and Climie A.R.W. (1966) Mixed meso-dermal tumors of the uterus. Cancer, 19, 1705–1710.
- Sasco A.J., Raffi F., Satge D., Goburdhun J., Fallouh B. and Leduc B. (1995) Endometrial mullerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. International Journal of Gynecology and Obstetrics, 48, 307–310.
- Schaepman-van Geuns E.J. (1970) Mixed tumours and carcinosarcomas of the uterus valuated five years after treatment. Cancer, 1, 72–77.
- Seoud M.A.F., Johnson F. and Weed J.C. (1993) Gynaecologic tumors in tamoxifen treated woman with breast cancer. Obstetrics and Gynecology, 82, 165–169.
- Silva E.G., Tornos C.S. and Follen-Mitchell M. (1994) Malignant neoplasms of uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. International Journal of Gynecological Pathology, 13, 248–258.
- Tsekeris P. and Dimou S. (2000) Synchronous endometrial carcinosarcoma and breast carcinoma: a case report. European Journal of Gynaecological Oncology, 21, 309–310.
- Zefmanowicoz A., Hildesheim A., Sherman ME., Sturgeon S., Kurman R., Barrett R., Berman M., Mortel R., Twiggs L., Wilbanks G. and Brinton L. (1998) Evidence for a common etiology for endometrial carcinomas and malignant mixed Mullerian tumours. Gynecologic Oncology, 69, 253–257.